Furthermore, P2X7 antagonists could represent an effective therapy to promote new vesslel formation and accelerate new bone formation by inhibiting excess exosomes secretion of hBMMSCs in HPP patients. The gene discussed is P2RX7; the disease is hypophosphatasia.